Drugs that target the oncogenic function of the Hippo pathway downstream effectors YAP1 and TAZ are therefore possible tools to compensate for the loss of Hippo-kinases, and to phenocopy RASSF1A function within cancer cells with either the loss of RASSF1A or defects in the Hippo pathway. This evidence concerns the gene RASSF1 and cancer.